TPU Pharma

TPU Pharma, officially known as The Pharma Unit, is a specialty pharmaceutical company based in Oss, Netherlands, that focuses on the development of value-added medicines. The company specializes in repurposing and reformulating existing off-patent drugs to address unmet medical needs, particularly in niche and orphan indications. Their lead program, TPU-001, is a proprietary liquid formulation of diazoxide designed for the treatment of congenital hyperinsulinism, aiming to provide a more stable and patient-friendly alternative to current treatments. TPU Pharma leverages its expertise in formulation science and regulatory strategy to bring improved therapeutic options to market efficiently. The company is headquartered at the Pivot Park life sciences hub and targets global orphan drug opportunities.